Nona Janikashvili

Dr. Nona Janikashvili


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2016 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
NJNona Janikashvili
Nona Janikashvili
MSMaxime Samson
Maxime Samson
EMEli Magen
Eli Magen
Tinatin ChikovaniTinatin Chikovani
Tinatin Chikovani

8 August 2016 in Case Reports in Hepatology
Verified
Journal Article
Open access
PDF file
MMMalkhaz Mizandari
Malkhaz Mizandari
TATamta Azrumelashvili
Tamta Azrumelashvili
NPNatela Paksashvili
Natela Paksashvili
NKNino Kikodze
Nino Kikodze
IPIa Pantsulaia
Ia Pantsulaia
Tinatin ChikovaniTinatin Chikovani
Tinatin Chikovani
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. Portal vein tumor thrombosis (PVTT) is a frequent entity in HCC, which strictly limits the gold standard treatment options such as surgical resection and transarterial chemoembolization. Therefore, the prognosis of patients with PVTT is extremely poor and an emergence of seeking an alternative option for intervention is inevitable. We present a case of a 60-year-old male patient with HCC induced PVTT who was subjected to the intraportal RFA and stenting-VesOpen procedure. No additional medical intervention was performed. The repeated CT performed 5 months after the VesOpen procedure revealed significant decrease of the tumor size, patent right, and main portal vein and a recanalization of the left portal vein, which was not processed. At this time point, liver functional tests, appetite, and general condition of the patient were improved evidently. This report designates the RFA as an instrumental option of therapeutic intervention for HCC patients with PVTT.

16 October 2017 in Immunotherapy
Verified
Journal Article
Closed access
MMMalkhaz Mizandari
Malkhaz Mizandari
NPNatela Paksashvili
Natela Paksashvili
NKNino Kikodze
Nino Kikodze
TATamta Azrumelashvili
Tamta Azrumelashvili
IPIa Pantsulaia
Ia Pantsulaia
Tinatin ChikovaniTinatin Chikovani
Tinatin Chikovani
Case report presents the successful treatment of unresectable liver metastasis in a patient with colon cancer. A 44-year-old male underwent right hemicolectomy followed by capecitabine for a moderately differentiated adenocarcinoma of the colon. 2 years later, a liver metastatic lesion was detected and had increased in size despite chemotherapy with capecitabine plus oxaliplatin (XELOX). Curative liver resection was conducted after conversion of unresectable tumor to resectable by transarterial chemoembolization followed by chemotherapy – irinotecan with fluorouracil and folinic acid (FOLFIRI). No recurrence was observed during 22-month follow-up after hepatectomy.

29 July 2022 in Radiology Case Reports
Verified
Journal Article
Open access
NTNino Toria
Nino Toria
NKNino Kikodze
Nino Kikodze
NJNona Janikashvili
Nona Janikashvili
IPIa Pantsulaia
Ia Pantsulaia
MMMalkhaz Mizandari
Malkhaz Mizandari
NHNagy Habib
Nagy Habib
Radiofrequency ablation (RFA) has widespread popularity due to its immune-modulation effects in many cancers. Optimal settings to apply RFA in pancreatic cancer, in which the advanced stage of the tumor at the diagnosis makes various therapeutic approaches fail, are still demanding. We report the case of a patient with unresectable pancreatic cancer in which 3 repetitive RFA has been applied over a period of 3 months. Results revealed an improvement in the patient's clinical condition associated with the reduced incidence of CD4+CD45RO+ T lymphocytes and declined TGF-β level in serum. The good quality of life and disease-free survival were maintained for the next months. Booster application of RFA procedure might be a promising option to improve the quality of life in pancreatic cancer patients.